Gilead Sciences reported second-quarter 2025 revenue of $7.08 billion and adjusted earnings of $2.01 a share, edging past Wall Street estimates. Sales rose 2 percent from a year earlier as growth in HIV therapies offset a sharp decline in demand for the Covid-19 antiviral Veklury. HIV franchise revenue climbed 7 percent to $5.1 billion, led by a 9 percent increase in flagship drug Biktarvy to $3.53 billion. Oncology medicine Trodelvy delivered $364 million, up 14 percent, while Veklury fell 44 percent to $121 million amid lower Covid-19 hospitalizations. Buoyed by the performance of its core portfolio and the recent U.S. approval of twice-yearly HIV prevention shot Yeztugo, the company lifted full-year guidance. It now projects 2025 product sales of $28.3 billion to $28.7 billion and non-GAAP earnings of $7.95 to $8.25 a share, up from prior targets. Forecasts for Veklury were cut to $1 billion. Gilead’s board approved a new $6 billion share-repurchase program and kept the quarterly dividend at $0.79 a share. The company ended June with $7.1 billion in cash, cash equivalents and marketable securities.